Floatz logo

RASDEGAFUSP ALFA

Recurrent Esophageal Carcinoma

Roswell Park Cancer Instituteprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

41 Active assets in the Recurrent Esophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC
Binimetinib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

RASDEGAFUSP ALFA is also rated in:

melanomaDormant
BB
Indicative ·
64 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
61 / 100
View asset →
Recurrent Ovarian CarcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →